Tuesday 9 June 2026

One To Watch

Windtree Therapeutics

A biotechnology company advancing late-stage interventions for critical cardiovascular disorders.

Company Overview

Want to Update your Company's Profile?


Latest Windtree Therapeutics News

Windtree Therapeutics agrees licensing deal for novel heart meds
18 January 2024
More Windtree Therapeutics news >


Today's issue

MHRA nod for Janssen’s Imaavy
Biotechnology
MHRA nod for Janssen’s Imaavy
9 June 2026
Pharmaceutical
MHRA launches AI sandbox to support medicines development and drug safety
9 June 2026
Biotechnology
AmMax Bio licenses ADC technology from Lonza
9 June 2026
Biotechnology
ARK Invest backs Cellares with $20 million as automated cell therapy manufacturing gains momentum
9 June 2026
Pharmaceutical
AlzeCure inks deal with Lilly for Alzheimer’s project
9 June 2026
Pharmaceutical
AstraZeneca advances oral GLP-1 elecoglipron into Phase III
9 June 2026
Biotechnology
Cartesian strikes licensing agreement with WestGene
9 June 2026




Copyright © The Pharma Letter 2026

 |  Headless Content Management with Blaze